Drug Profile
MEDI 560
Alternative Names: MEDI-560; PIV-3 vaccine - AstraZeneca; rHPIV3cp45Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parainfluenza virus infections
Most Recent Events
- 01 Dec 2008 Phase-I/IIa development is ongoing in USA
- 26 Jul 2007 Phase-I clinical trials in Parainfluenza virus infections in USA (Intranasal)